- Home
- News
- us virgislands
- disease pathogens
Refine by
Disease Pathogens Articles & Analysis
24 news found
It is frequently a life-threatening infection warns the Centers for Disease Control and Prevention (CDC). The agency also cautions that while most cases of mucormycosis are sporadic, outbreaks have occurred. ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. ...
If this innovative approach is proven to be successful, it may also be applicable for developing vaccines against other pathogens in the CEPI portfolio, including ‘Disease X’ - unknown pathogens with pandemic potential that have yet to emerge. ...
Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and ...
By using Leaf’s proprietary transient expression technology Supravec®, in partnership with Professor Mark Banfield’s lab at the John Innes Centre, the team will explore the mechanistic biology of plant proteins involved in pathogen recognition and disease resistance. The research led by Professor Banfield’s group at the John Innes Centre ...
April 25, 2022 at 9:30 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 25, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office (“US PTO”) has granted the patent regarding ...
D’Herelle would later apply this knowledge to successfully treat children suffering from severe dysentery at the Hospital des Enfants Malades in Paris and create cures for other pathogens like cholera and typhoid. Encouraged by d’Herelle’s contributions and similar studies, there was soon overwhelming excitement surrounding phage therapy and its success in ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious ...
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. ...
It entails technology that allows the efficient production of disease-specific antigens in so-called protein bodies, nanosized protein particles that can be administered to the body as vaccines. ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that it has successfully developed an ImplaVax®-enabled, solid-dose recombinant H7N9 pandemic influenza vaccine and delivered ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), ...
Listeriosis is a foodborne infectious disease caused by the pathogen Listeria monocytogenes and is particularly serious for pregnant women and immunocompromised persons. The pathogen is spread mainly through spoiled and contaminated food or animal feed. ...
Current technologies involve extensive trial and error to define exactly which parts of the pathogen induces robust immunity. These so called immunodominant epitopes need to be identified for the general population. ...
Harmful chemicals begin to build up and potentially pathogenic microorganisms start to grow. It takes only days for dangerous concentrations to form, but many buildings will remain closed for months. ...
When we entered the field of infectious disease diagnostics, we made a goal to innovate what we called the BioFire “Big 5”—five cutting-edge syndromic testing solutions for the most common and most dangerous infectious diseases. ...
He continued, "In addition to these, there are several other diseases transmitted by mosquitoes that can be harmful to health and even deadly, and this site serves as a comprehensive and educational resource where people can learn more about mosquitoes and the harm they are capable of inflicting." "By arming both the public and agencies, such as MADs and PHOs that work to ...
The last few months have brought flooding to many parts of Texas and there are now reports of increasing infection rates due to microbial pathogens commonly associated with feces. Just this month, KRGV broadcast a report about a dramatic increase in the number of cases of campylobacteriosis across the state. ...